PubMed · 15218811
Mitoxantrone as a potential therapy for primary progressive multiple sclerosis.
Abstract
Mitoxantrone (Novantrone) was the first drug approved in western Europe and North America for treatment of secondary progressive multiple sclerosis (SPMS) and progressive relapsing MS (PRMS). Pharmacological properties of mitoxantrone, its role in SPMS, the study rational and design of an ongoing multi-centre, double blind, randomized, placebo-controlled phase 2 trial will be outlined in this article.
Explore related subjects
Keep this discovery
Explore connections, maps & timelines
Olaf Stüve, Mariko Kita, Daniel Pelletier, Robert J Fox, Jerome Stone, Donald E Goodkin, Scott S Zamvil. 2004. Mitoxantrone as a potential therapy for primary progressive multiple sclerosis.. https://doi.org/10.1191/1352458504ms1032oa
Cite the original work for its findings. Save a collection to share your selection of sources.